CA2790500A1 - Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases - Google Patents

Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases Download PDF

Info

Publication number
CA2790500A1
CA2790500A1 CA2790500A CA2790500A CA2790500A1 CA 2790500 A1 CA2790500 A1 CA 2790500A1 CA 2790500 A CA2790500 A CA 2790500A CA 2790500 A CA2790500 A CA 2790500A CA 2790500 A1 CA2790500 A1 CA 2790500A1
Authority
CA
Canada
Prior art keywords
emp2
seq
inhibitor
antibody
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2790500A
Other languages
English (en)
French (fr)
Inventor
Lynn K. Gordon
Jonathan Braun
Shawn Morales
David G. Telander
Madhuri Wadehra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Veterans Affairs
University of California San Diego UCSD
Original Assignee
US Department of Veterans Affairs
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Veterans Affairs, University of California San Diego UCSD filed Critical US Department of Veterans Affairs
Publication of CA2790500A1 publication Critical patent/CA2790500A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2790500A 2010-02-19 2011-02-22 Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases Abandoned CA2790500A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30607310P 2010-02-19 2010-02-19
US61/306,073 2010-02-19
PCT/US2011/025772 WO2011103599A2 (en) 2010-02-19 2011-02-22 Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases

Publications (1)

Publication Number Publication Date
CA2790500A1 true CA2790500A1 (en) 2011-08-25

Family

ID=44483632

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2790500A Abandoned CA2790500A1 (en) 2010-02-19 2011-02-22 Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases

Country Status (6)

Country Link
US (1) US20130034555A1 (https=)
EP (1) EP2536433B1 (https=)
JP (1) JP5852968B2 (https=)
AU (1) AU2011217785B2 (https=)
CA (1) CA2790500A1 (https=)
WO (1) WO2011103599A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150079089A1 (en) * 2012-02-06 2015-03-19 The Regents Of The University Of California Emp2 regulates angiogenesis in cancer cells through induction of vegf
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
JP6533078B2 (ja) * 2015-03-20 2019-06-19 テルモ株式会社 画像診断装置、その制御方法、プログラム及びコンピュータ可読記憶媒体
US11890340B2 (en) * 2018-04-30 2024-02-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of epithelial membrane protein 2 [EMP2] targeting agents in treating lung disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5264188A (en) 1991-01-22 1993-11-23 Phillips Petroleum Company Multi-stage hydrotreating process and apparatus
PT1221918E (pt) 1999-10-21 2005-06-30 Alcon Inc Administracao de drogas sub-tenon
GB0004212D0 (en) 2000-02-23 2000-04-12 Plexus Ocean Syst Ltd Pipe joint
KR20050047118A (ko) 2002-09-18 2005-05-19 알러간, 인코포레이티드 안과 임플란트의 수송을 위한 방법 및 장치
US7615219B2 (en) 2003-01-16 2009-11-10 Life Sciences Research Partners Vzw Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8648052B2 (en) * 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
BRPI0709425A2 (pt) * 2006-03-29 2011-07-12 Genentech, Inc. uso de um antagonista do vegf e método in vitro para diagnosticar um tumor resistente
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US20090081277A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
JP5911805B2 (ja) * 2009-11-20 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ）

Also Published As

Publication number Publication date
EP2536433A2 (en) 2012-12-26
JP2013520446A (ja) 2013-06-06
AU2011217785A9 (en) 2015-06-18
AU2011217785A1 (en) 2012-09-13
WO2011103599A9 (en) 2011-12-08
US20130034555A1 (en) 2013-02-07
AU2011217785B2 (en) 2015-06-18
EP2536433B1 (en) 2017-08-02
JP5852968B2 (ja) 2016-02-03
WO2011103599A2 (en) 2011-08-25
EP2536433A4 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
JP6796184B2 (ja) 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
CN109715189B (zh) 靶向VE-PTP(HPTP-β)的人源化单克隆抗体
US10961304B2 (en) Method of reducing the effect of a stroke comprising administering an inhibitor of vascular endothelial growth factor B (VEGF-B)
KR20250166355A (ko) 안과 질환의 치료
KR20170082526A (ko) 안 질환의 치료 방법
HK1201196A1 (en) Treatment of ocular disease
AU2004242586B2 (en) Method of treating corneal transplant rejection by using VEGF antagonists
AU2011217785B2 (en) Epithelial membrane protein 2 (EMP2) binding reagents and their therapeutic uses in ocular diseases
JP2015528004A (ja) 慢性腎臓病（ｃｋｄ）を予防および処置するための方法
US20050129685A1 (en) Use of IL-1 blockers to prevent corneal inflammation and neovascularization
KR101749380B1 (ko) Pdk 억제제의 스크리닝 방법 및 pdk 억제제의 용도
CN108779173A (zh) 通过拮抗胎盘生长因子抑制眼后部纤维化
US20240285800A1 (en) Retinal Disorders
WO2025116819A1 (en) Methods of treating neovascular eye diseases
HK40121389A (zh) 预测对il-6拮抗剂的反应
CN120112551A (zh) 预测对il-6拮抗剂的反应
WO2017117512A2 (en) Compositions and methods for treating retinopathy
HK1242603B (en) Method of treating or preventing stroke

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160215

FZDE Discontinued

Effective date: 20200909